BPC-157 Heals NSAID Gut Damage AND Reduces Arthritis at the Same Time
BPC-157 simultaneously protected against NSAID-induced gut damage and improved chronic adjuvant arthritis in rats, showing dual gastroprotective and anti-inflammatory/analgesic effects.
Quick Facts
What This Study Found
BPC-157 both protected against NSAID-induced GI lesions and improved chronic adjuvant arthritis, demonstrating simultaneous gastroprotective and anti-inflammatory effects.
Key Numbers
How They Did This
Rat model of adjuvant arthritis with concurrent NSAID administration. BPC-157 was tested for both gastroprotective effects (against NSAID damage) and arthritis improvement.
Why This Research Matters
NSAIDs are the most common treatment for arthritis but cause serious gut damage. A peptide that protects the gut while also reducing inflammation could solve a major clinical dilemma.
The Bigger Picture
This study positioned BPC-157 as a potential co-therapy with NSAIDs — protecting against their gut side effects while adding its own anti-inflammatory benefit.
What This Study Doesn't Tell Us
Animal study; adjuvant arthritis may not fully model human rheumatoid arthritis. Specific doses, timing, and quantitative improvements not detailed.
Questions This Raises
- ?Could BPC-157 be co-administered with NSAIDs to prevent gastropathy while enhancing anti-inflammatory effects?
- ?Does BPC-157 work through the same anti-inflammatory pathways as NSAIDs?
Trust & Context
- Key Stat:
- Protects gut + fights arthritis BPC-157 simultaneously shielded against NSAID stomach damage and improved chronic adjuvant arthritis
- Evidence Grade:
- Moderate animal evidence demonstrating dual therapeutic effects in a clinically relevant model.
- Study Age:
- Published in 1997, this is frequently cited as evidence for BPC-157's anti-inflammatory properties beyond gut healing.
- Original Title:
- Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats.
- Published In:
- Journal of physiology, Paris, 91(3-5), 113-22 (1997)
- Authors:
- Sikiric, P(36), Seiwerth, S(42), Grabarevic, Z(12), Rucman, R, Petek, M, Jagic, V, Turkovic, B, Rotkvic, I, Mise, S, Zoricic, I, Konjevoda, P, Perovic, D, Simicevic, V, Separovic, J, Hanzevacki, M, Ljubanovic, D, Artukovic, B, Bratulic, M, Tisljar, M, Rekic, B, Gjurasin, M, Miklic, P, Buljat, G
- Database ID:
- RPEP-00428
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why is this finding important for NSAID users?
NSAIDs like ibuprofen and naproxen cause stomach ulcers in many users. BPC-157 could potentially protect the stomach while the NSAID treats inflammation — addressing both sides of a common clinical problem.
Does BPC-157 replace NSAIDs?
Not necessarily. This study shows BPC-157 has its own anti-inflammatory and pain-relieving properties alongside gastroprotection. It might complement NSAIDs or potentially allow lower NSAID doses.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00428APA
Sikiric, P; Seiwerth, S; Grabarevic, Z; Rucman, R; Petek, M; Jagic, V; Turkovic, B; Rotkvic, I; Mise, S; Zoricic, I; Konjevoda, P; Perovic, D; Simicevic, V; Separovic, J; Hanzevacki, M; Ljubanovic, D; Artukovic, B; Bratulic, M; Tisljar, M; Rekic, B; Gjurasin, M; Miklic, P; Buljat, G. (1997). Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats.. Journal of physiology, Paris, 91(3-5), 113-22.
MLA
Sikiric, P, et al. "Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats.." Journal of physiology, 1997.
RethinkPeptides
RethinkPeptides Research Database. "Pentadecapeptide BPC 157 positively affects both non-steroid..." RPEP-00428. Retrieved from https://rethinkpeptides.com/research/sikiric-1997-pentadecapeptide-bpc-157-positively
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.